Study wrapper · #1364
Case report: Tirzepatide-responsive refractory diabetes mellitus in an adult female with prader-willi syndrome.
Editor's note
A single case, so no generalizable conclusions — but Prader-Willi syndrome is a population where appetite-driven obesity is uniquely severe and therapeutic options are thin, which gives the observation some weight. The within-patient comparison (tirzepatide succeeding where a GLP-1 mono-agonist fell short) is suggestive of the added GIP component mattering, though switching effects and dose differences can't be ruled out. Small PWS trials of incretin therapies would be the logical follow-up.
Plain-language abstract
A woman with Prader-Willi syndrome — a genetic disorder marked by relentless hunger and severe obesity — had diabetes that resisted a five-drug regimen, but after her GLP-1 drug was swapped for tirzepatide she saw notable appetite suppression, weight reduction, and better blood sugar control.